Equities analysts expect that GW Pharmaceuticals PLC- (NASDAQ:GWPH) will post $2.14 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for GW Pharmaceuticals PLC-‘s earnings. The lowest sales estimate is $2.00 million and the highest is $2.27 million. GW Pharmaceuticals PLC- posted sales of $2.54 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15.7%. The business is expected to report its next earnings results on Tuesday, February 6th.

On average, analysts expect that GW Pharmaceuticals PLC- will report full-year sales of $2.14 million for the current year, with estimates ranging from $9.36 million to $60.93 million. For the next financial year, analysts forecast that the business will report sales of $219.01 million per share, with estimates ranging from $93.22 million to $322.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings data on Monday, December 4th. The biopharmaceutical company reported ($2.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.45). GW Pharmaceuticals PLC- had a negative net margin of 1,607.85% and a negative return on equity of 40.42%.

A number of analysts recently issued reports on the company. Cowen reissued an “outperform” rating and set a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $208.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Zacks Investment Research cut GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. BidaskClub cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Leerink Swann restated an “outperform” rating and set a $153.00 target price (down from $160.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $148.78.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Alps Advisors Inc. raised its holdings in GW Pharmaceuticals PLC- by 9.1% during the third quarter. Alps Advisors Inc. now owns 24,921 shares of the biopharmaceutical company’s stock valued at $2,529,000 after buying an additional 2,081 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in GW Pharmaceuticals PLC- by 48.3% during the second quarter. Goldman Sachs Group Inc. now owns 48,559 shares of the biopharmaceutical company’s stock valued at $4,868,000 after buying an additional 15,816 shares in the last quarter. Jennison Associates LLC raised its holdings in GW Pharmaceuticals PLC- by 0.4% during the third quarter. Jennison Associates LLC now owns 492,480 shares of the biopharmaceutical company’s stock valued at $49,982,000 after buying an additional 1,759 shares in the last quarter. Janus Henderson Group PLC bought a new position in GW Pharmaceuticals PLC- during the second quarter valued at about $70,128,000. Finally, Wells Fargo & Company MN raised its holdings in GW Pharmaceuticals PLC- by 21.8% during the second quarter. Wells Fargo & Company MN now owns 13,962 shares of the biopharmaceutical company’s stock valued at $1,399,000 after buying an additional 2,500 shares in the last quarter. Institutional investors own 74.57% of the company’s stock.

Shares of GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $132.43 on Thursday. The stock has a market capitalization of $3,360.00, a price-to-earnings ratio of -18.39 and a beta of 2.65. GW Pharmaceuticals PLC- has a 12-month low of $92.65 and a 12-month high of $140.52. The company has a current ratio of 7.59, a quick ratio of 7.47 and a debt-to-equity ratio of 0.02.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/18/zacks-analysts-expect-gw-pharmaceuticals-plc-gwph-will-announce-quarterly-sales-of-2-14-million.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.